PATENT CLAIM ANALYSIS

Application Number: 16242704
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2020-01
Patent Classification: ["424", "450000"]

Abstract:
Liposomes termed as small unilamellar vesicles (SUVs), can be synthesized in the 20-50 nm size range, but encounter challenges such as instability and aggregation leading to inter-particle fusion. This limits their use as a therapeutic delivery agent. Increasing the surface negative charge of SUVs, via the attachment of anionic entities such as DNA/RNA, increases the colloidal stability of these vesicles. Additionally, the dense spherical arrangement and radial orientation of nucleic acids exhibits unique chemical and biological properties, unlike their linear counterparts. These liposomal particles, are non-toxic and though anionic, can efficiently enter cells without the aid of ancillary cationic transfection agents in a non-immunogenic fashion. These exceptional properties allow their use as delivery agents for gene regulation in different therapies and offer an alternative platform to metal core spherical nucleic acids.

Claim (Index 27):
The method of  claim 26 , wherein the TLR9 agonist is a CpG-containing oligonucleotide.

Metadata:
- Claim Count in Document: 77.0
- Percentile: 99.0
- Lexical Diversity: 1.48485
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15101523', '15315538', '09807332', '15097607', '14113371']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7437333628282857
- 35 USC 102 Novelty (BERT): 0.6650355457288956
- Combined Prediction Score: 0.7358635811183467
- Mean Citation Score: 354.79808
- Max Citation Score: 680.0258
- Similarity Product: 519.9410649854541

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test